Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5204027 | 0.96 | CCR2 (0.65) | CCR2CCR5 | |
| SCHEMBL5208303 | 0.95 | CCR2 (0.64) | CCR2CCR5 | |
| SCHEMBL5209624 | 0.95 | CCR2 (0.63) | CCR2CCR5 | |
| SCHEMBL5210238 | 0.94 | CCR2 (0.55) | CCR2CCR5 | |
| SCHEMBL5241768 | 0.90 | CCR2 (0.67) | CCR2CCR5 | |
| SCHEMBL3026537 | 0.90 | CCR2 (0.77) | CCR2CCR5 | |
| SCHEMBL5208241 | 0.90 | CCR2 (0.67) | CCR2CCR5 | |
| SCHEMBL5209195 | 0.90 | CCR2 (0.66) | CCR2CCR5 | |
| SCHEMBL7682451 | 0.90 | CCR2 (0.66) | CCR2CCR5 | |
| SCHEMBL7918243 | 0.89 | CCR2 (0.65) | CCR2CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | claimed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | claimed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | claimed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | claimed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| EP-1040103-B1 | ANILIDE DERIVATIVE, PRODUCTION AND USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1236476-A1 | MEDICINAL COMPOSITIONS FOR ORAL USE | Takeda Chemical Industries, Ltd. (JP) | 2002-09-04 | — | — | EP | disclosed |
| US-6413947-B1 | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-07-02 | — | — | US | disclosed |
| US-6376536-B1 | VIRICIDES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-04-23 | — | — | US | disclosed |
| US-6268354-B1 | Pharmaceutical composition for antagonizing CCR5 comprising anilide derivative | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-07-31 | — | — | US | disclosed |
| US-6172061-B1 | AIDS THERAPY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2001-01-09 | — | — | US | disclosed |
| US-6166006-A | Anilide derivative, production and use thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-12-26 | — | — | US | disclosed |
| US-6096780-A | ANTIVIRAL COMPOUND USEFUL FOR TREATING HIV VIRUSES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2000-08-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154016-A1 | Preventives for hiv infection | CCR5, CCR2, CCR1 | CCR2 2/4885CCR5 1/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.